HRP20161279T1 - Kombinirani preparati s antagonistom citokina i ortikosteroidom - Google Patents
Kombinirani preparati s antagonistom citokina i ortikosteroidom Download PDFInfo
- Publication number
- HRP20161279T1 HRP20161279T1 HRP20161279TT HRP20161279T HRP20161279T1 HR P20161279 T1 HRP20161279 T1 HR P20161279T1 HR P20161279T T HRP20161279T T HR P20161279TT HR P20161279 T HRP20161279 T HR P20161279T HR P20161279 T1 HRP20161279 T1 HR P20161279T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical compound
- antagonist
- cytokine antagonist
- protein
- interleukin
- Prior art date
Links
- 239000000430 cytokine receptor antagonist Substances 0.000 title claims 27
- 239000003246 corticosteroid Substances 0.000 title claims 11
- 238000002360 preparation method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 30
- 102000015696 Interleukins Human genes 0.000 claims 12
- 108010063738 Interleukins Proteins 0.000 claims 12
- 239000005557 antagonist Substances 0.000 claims 8
- 239000003102 growth factor Substances 0.000 claims 8
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 6
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 6
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 6
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 6
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 6
- 229960004238 anakinra Drugs 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940076372 protein antagonist Drugs 0.000 claims 5
- 238000002648 combination therapy Methods 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- -1 alclomethasone Chemical compound 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 claims 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 claims 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 208000023835 Tendon disease Diseases 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 229960003099 amcinonide Drugs 0.000 claims 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 229960002537 betamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 229960002842 clobetasol Drugs 0.000 claims 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims 1
- 229960001146 clobetasone Drugs 0.000 claims 1
- XXIFVOHLGBURIG-OZCCCYNHSA-N clobetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)CC2=O XXIFVOHLGBURIG-OZCCCYNHSA-N 0.000 claims 1
- 229960004299 clocortolone Drugs 0.000 claims 1
- YMTMADLUXIRMGX-RFPWEZLHSA-N clocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O YMTMADLUXIRMGX-RFPWEZLHSA-N 0.000 claims 1
- 229960002219 cloprednol Drugs 0.000 claims 1
- YTJIBEDMAQUYSZ-FDNPDPBUSA-N cloprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C=C(Cl)C2=C1 YTJIBEDMAQUYSZ-FDNPDPBUSA-N 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- 229960001145 deflazacort Drugs 0.000 claims 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 claims 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 1
- 229960002593 desoximetasone Drugs 0.000 claims 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960004154 diflorasone Drugs 0.000 claims 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 claims 1
- 229960004091 diflucortolone Drugs 0.000 claims 1
- OGPWIDANBSLJPC-RFPWEZLHSA-N diflucortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O OGPWIDANBSLJPC-RFPWEZLHSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229940011871 estrogen Drugs 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229960002011 fludrocortisone Drugs 0.000 claims 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims 1
- 229960004511 fludroxycortide Drugs 0.000 claims 1
- 229960003469 flumetasone Drugs 0.000 claims 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 claims 1
- 229940043075 fluocinolone Drugs 0.000 claims 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims 1
- 229960000785 fluocinonide Drugs 0.000 claims 1
- 229960005355 fluocortin Drugs 0.000 claims 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 claims 1
- 229960003973 fluocortolone Drugs 0.000 claims 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 claims 1
- 229960000618 fluprednisolone Drugs 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 229960002383 halcinonide Drugs 0.000 claims 1
- 229960002475 halometasone Drugs 0.000 claims 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 239000002395 mineralocorticoid Substances 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 229960002858 paramethasone Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
Claims (17)
1. Farmaceutski spoj koji sadrži kortikosteroid zajedno s antagonistom citokina, dodatnim antagonistom citokina i opciono faktorom rasta, pri čemu je antagonist citokina rekombinantni antagonist interleukin IL-1Ra proteina, posebno anakinra, a dodatni antagonist citokina je prirodni antagonist interleukin IL-1Ra proteina, posebno ortokin, i pri čemu je farmaceutski spoj pogodan za lokalnu primjenu lijeka..
2. Farmaceutski spoj koji sadrži antagonist citokina, dodatni antagonist citokina i opciono faktor rasta za uporabu u kombiniranoj terapiji zajedno s kortikosteroidom, pri čemu je antagonist citokina rekombinantni antagonist interleukin IL-1Ra protein, posebno anakinra, a dodatni antagonist citokina je prirodni antagonist interleukin IL-1Ra protein, posebno ortokin, i pri čemu je farmaceutski spoj pogodan za lokalnu primjenu lijeka.
3. Farmaceutski spoj koji sadrži kortikosteroid za uporabu u kombiniranoj terapiji zajedno s antagonistom citokina, dodatnim antagonistom citokina i opciono faktorom rasta, pri čemu je antagonist citokina rekombinantni antagonist interleukin IL-1Ra protein, posebno anakinra, a dodatni antagonist citokina je prirodni antagonist interleukin IL-1Ra protein, posebno ortokin, i pri čemu je farmaceutski spoj pogodan za lokalnu primjenu lijeka.
4. Komplet koji sadrži farmaceutski spoj koji sadrži antagonist citokina i opciono faktor rasta, farmaceutski spoj koji sadrži kortikosteroid, a osim toga dodatni antagonist citokina, pri čemu je antagonist citokina rekombinantni antagonist interleukin IL-1Ra protein, a posebno anakinra, a dodatni antagonist citokina je prirodni antagonist interleukin IL-1Ra protein, a posebno orthokin, i pri čemu je farmaceutski spoj pogodan za lokalnu primjenu.
5. Farmaceutski spoj prema zahtjevu 2 ili 3 ili komplet prema zahtjevu 4, pri čemu je/su farmaceutski spoj (evi) predviđen(i) za istodobnu ili sekvencijalnu primjenu antagonista citokina odn. faktora rasta i kortikosteroida.
6. Farmaceutski spoj ili komplet prema jednom od zahtjeva 1, 2 i 4 do 5, pri čemu je antagonist citokina prisutan u koncentraciji od 0,5 do 150 mg/dozi u farmaceutskom spoju koje sadrži antagonist citokina.
7. Farmaceutski spoj ili komplet prema jednom od zahtjeva 1 do 6, pri čemu je kortikosteroid
(a) glukokortikoid kao na primjer kortizon, hidrokortizon, prednison, prednisolon, kloprednol, deflazakort, fluokortin, triamcinolon, deksametazon, metilprednisolon, fluprednisolon, klokortolon, klobetazon, alklometazon, flumetazon, flupredniden, flurandrenolon, betametazon, beklometazon, fluokortolon, mometazon, flutikazon, halometazon, fluocinolon, diflorason, dezoksimetazon, fluocinonid, amcinonid, halcinonid, diflukortolon, klobetazol, parametazon;
(b) mineralni kortikoid kao na primjer aldosteron, ezoksikortikosteron i fludrokortizon; ili
(c) androgen kao na primjer dehidroepiandrosteron (DHEA) i estrogeni; ili njegova sol, ester ili prolijek.
8. Farmaceutski spoj ili komplet prema jednom od zahtjeva 1 i 3 do 7, pri čemu kortikosteroid u koncentraciji od 1 do 80 mg/dozi postoji u farmaceutskom spoju koji sadrži kortikosteroid.
9. Farmaceutski spoj ili komplet prema jednom od zahtjeva 1 do 8, pri čemu je faktor rasta izabran iz grupe koja se sastoji od TGF-�, IGF, BMP, HGF i VEGF.
10. Farmaceutski spoj ili komplet prema jednom od zahtjeva 1 do 9 za uporabu pri liječenju bolesti zglobova poput artroze i upalnog gubitka hrskavice, bolesti tetiva i/ili degenerativnih bolesti kralješnice.
11. Farmaceutski spoj ili komplet prema zahtjevu 10, pri čemu je artroza aktivirana artroza ili inflamatorna artroza.
12. Farmaceutski spoj ili komplet prema zahtjevu 10, pri čemu je degenerativna bolest kralješnice diskus hernija.
13. Farmaceutski spoj ili komplet prema jednom od zahtjeva 1 do 9 za uporabu pri liječenju neurodermitisa ili alopecije areate.
14. Farmaceutski spoj ili komplet prema jednom od zahtjeva 1 do 9, ili farmaceutski spoj ili komplet za uporabu prema jednom od zahtjeva 10 do 13, pri čemu je lokalna primjena lijeka izabrana iz grupe koja se sastoji od ubrizgavanja u bolesti pogođen dio tijela, a posebno u bolesti pogođen zglob, u bolesti pogođeni korijen živca ili u pogođeni međupršljenski disk, ili u njihovo lokalno okruženje; intraartikularno ubrizgavanje; i lokalna primjena lijeka.
15. Farmaceutski spoj ili komplet prema jednom od zahtjeva 1 do 9 i 14, ili farmaceutski spoj ili komplet za uporabu prema jednom od zahtjeva 10 do 14, pri čemu farmaceutski spoj(evi) sadrž(i/e) nosač i/ili ekscipijent.
16. Uporaba antagonista citokina, dodatnog antagonista citokina i opciono faktora rasta za proizvodnju farmaceutskog spoja za uporabu u kombiniranoj terapiji zajedno s kortikosteroidom, pri čemi je antagonist citokina rekombinantni antagonist interleukina IL-1Ra protein, posebno anakinra, dodatni antagonist citokina je prirodni antagonist interleukin IL-1 Ra proteina, posebno ortokin, i pri čemu je farmaceutski spoj pogodan za lokalno davanje.
17. Upotreba kortikosteroida za proizvodnju farmaceutskog spoja za uporabu u kombiniranoj terapiji zajedno s antagonistom citokina, dodatnog antagonista citokina i opciono faktorom rasta, pri čemu je antagonist citokina rekombinantni antagonist interleukin IL-1Ra protein, posebno anakinra, dodatni antagonist citokina prirodnog antagonista interleukin IL-1Ra proteinA, posebno ortokin, i pri čemu je farmaceutski spoj pogodan za lokalno davanje.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102009057495 | 2009-12-10 | ||
PCT/EP2010/069427 WO2011082951A1 (de) | 2009-12-10 | 2010-12-10 | Kombinationspräparate mit cytokin-antagonist und corticosteroid |
EP10800714.7A EP2437748B8 (de) | 2009-12-10 | 2010-12-10 | Kombinationspräparate mit cytokin-antagonist und corticosteroid |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161279T1 true HRP20161279T1 (hr) | 2016-12-02 |
Family
ID=43707934
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161268TT HRP20161268T1 (hr) | 2009-12-10 | 2016-10-04 | Kombinirani preparat koji se sastoji od egzozoma i kortikosteroida |
HRP20161279TT HRP20161279T1 (hr) | 2009-12-10 | 2016-10-05 | Kombinirani preparati s antagonistom citokina i ortikosteroidom |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161268TT HRP20161268T1 (hr) | 2009-12-10 | 2016-10-04 | Kombinirani preparat koji se sastoji od egzozoma i kortikosteroida |
Country Status (22)
Country | Link |
---|---|
US (3) | US9724391B2 (hr) |
EP (2) | EP2437748B8 (hr) |
JP (2) | JP5907886B2 (hr) |
KR (2) | KR101786444B1 (hr) |
CN (2) | CN107096031A (hr) |
AU (2) | AU2010340999B2 (hr) |
BR (2) | BR112012014066A2 (hr) |
CA (2) | CA2781576C (hr) |
CY (2) | CY1118081T1 (hr) |
DE (1) | DE202009017772U1 (hr) |
DK (2) | DK2437748T5 (hr) |
ES (2) | ES2594896T3 (hr) |
HR (2) | HRP20161268T1 (hr) |
HU (2) | HUE029979T2 (hr) |
LT (2) | LT2437747T (hr) |
MX (2) | MX2012006430A (hr) |
PL (2) | PL2437748T3 (hr) |
PT (2) | PT2437747T (hr) |
RS (2) | RS55217B1 (hr) |
RU (2) | RU2557897C2 (hr) |
SI (2) | SI2437748T1 (hr) |
WO (2) | WO2011082950A1 (hr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170189475A9 (en) * | 2009-12-10 | 2017-07-06 | Orthogen Ag | Combination preparation comprising a cytokine antagonist and corticosteroid |
DE102012019088A1 (de) * | 2012-09-28 | 2014-04-03 | Orthogen Ag | Antibakterielle Arzneimittelpräparate |
CN104673749B (zh) * | 2015-02-12 | 2017-10-20 | 江苏大学 | 一种粒细胞样髓源性抑制细胞来源exosomes及其应用 |
TW201722442A (zh) * | 2015-11-13 | 2017-07-01 | 奧爾托金公司 | 對老化相關病症有效之醫藥製劑 |
AU2017313163B2 (en) * | 2016-08-17 | 2019-01-03 | Orthogen Ag | Anti-ageing pharmaceutical preparation |
AU2017313844B2 (en) | 2016-08-19 | 2023-10-12 | University Of Florida Research Foundation, Incorporated | Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus |
WO2018056481A1 (ko) * | 2016-09-23 | 2018-03-29 | ㈜프로스테믹스 | 면역 억제 및 항염증성 조성물 |
CN110225923A (zh) | 2016-12-07 | 2019-09-10 | 佛罗里达大学研究基金会有限公司 | IL-1Ra cDNA |
CN108175759B (zh) * | 2016-12-08 | 2021-03-19 | 暨南大学 | 一种抗肿瘤靶向给药系统及其制备方法与应用 |
EA038300B1 (ru) * | 2017-04-18 | 2021-08-06 | Юниверсити Оф Флорида Рисерч Фаундейшен, Инкорпорейтед | Кднк il-1ra |
CN108619114B (zh) * | 2018-05-02 | 2020-08-11 | 东南大学 | 一种负载地塞米松的巨噬细胞源微囊泡及其制备方法和应用 |
CN109078171A (zh) * | 2018-09-10 | 2018-12-25 | 因之彩生物科技(武汉)有限公司 | 一种外用组合物及其应用以及外用治疗剂 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2793159A (en) * | 1955-03-09 | 1957-05-21 | Upjohn Co | Stable hydrocortisone solution |
KR0148009B1 (ko) | 1988-05-27 | 1998-08-01 | 그래고리 비. 아보트 | 인터루킨-1 억제제 |
GB9206861D0 (en) * | 1992-03-28 | 1992-05-13 | Univ Manchester | Wound healing and treatment of fibrotic disorders |
IL110589A0 (en) | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
BR9707325A (pt) | 1996-02-09 | 1999-04-13 | Amgen Inc | Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma |
JP2001511010A (ja) * | 1997-02-06 | 2001-08-07 | ジェネティックス・インスチチュート・インコーポレーテッド | ヒトsdf−5蛋白および組成物 |
AT411901B (de) | 1997-08-16 | 2004-07-26 | Orthogen Gentechnologie Gmbh | Verfahren zur induktion von therapeutisch wirksamen proteinen durch inkubation einer körperflüssigkeit in einer einen induktor enthaltenden spritze |
DE19903876B4 (de) | 1999-02-01 | 2006-09-28 | Orthogen Gentechnologie Gmbh | Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten |
DE10213780A1 (de) | 2002-03-22 | 2003-11-27 | Orthogen Ag | Verfahren und Mittel zur Herstellung therapeutisch interessanter Blutzusammensetzungen |
KR20070058441A (ko) | 2004-07-01 | 2007-06-08 | 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 면역억제성 엑소솜 |
DE102004036840B4 (de) | 2004-07-29 | 2012-04-19 | Orthogen Ag | Verfahren und Mittel zur Gewinnung von thrombocytenreichem Plasma |
TW200740441A (en) * | 2005-06-17 | 2007-11-01 | Combinatorx Inc | Methods and reagents for the treatment of inflammatory disorders |
US20080207577A1 (en) | 2005-07-11 | 2008-08-28 | Astrazeneca Ab | Combination I |
US7292185B2 (en) * | 2005-10-04 | 2007-11-06 | Csi Wireless Inc. | Attitude determination exploiting geometry constraints |
RU2008122978A (ru) * | 2005-11-09 | 2009-12-20 | Комбинаторкс, Инкорпорейтед (Us) | Способы, композиции и наборы для лечения медицинских состояний |
WO2007075896A2 (en) * | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
DE102006005016A1 (de) | 2006-02-03 | 2007-08-16 | Orthogen Ag | Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung |
-
2009
- 2009-12-10 DE DE202009017772U patent/DE202009017772U1/de not_active Expired - Lifetime
-
2010
- 2010-12-10 RS RS20160811A patent/RS55217B1/sr unknown
- 2010-12-10 HU HUE10800714A patent/HUE029979T2/en unknown
- 2010-12-10 RU RU2012128877/15A patent/RU2557897C2/ru active
- 2010-12-10 EP EP10800714.7A patent/EP2437748B8/de active Active
- 2010-12-10 MX MX2012006430A patent/MX2012006430A/es active IP Right Grant
- 2010-12-10 HU HUE10800713A patent/HUE030460T2/en unknown
- 2010-12-10 EP EP10800713.9A patent/EP2437747B8/de active Active
- 2010-12-10 DK DK10800714.7T patent/DK2437748T5/en active
- 2010-12-10 CN CN201611074699.1A patent/CN107096031A/zh active Pending
- 2010-12-10 WO PCT/EP2010/069426 patent/WO2011082950A1/de active Application Filing
- 2010-12-10 ES ES10800714.7T patent/ES2594896T3/es active Active
- 2010-12-10 AU AU2010340999A patent/AU2010340999B2/en active Active
- 2010-12-10 US US13/142,573 patent/US9724391B2/en active Active
- 2010-12-10 AU AU2010341000A patent/AU2010341000B2/en active Active
- 2010-12-10 PL PL10800714T patent/PL2437748T3/pl unknown
- 2010-12-10 CN CN2010800556328A patent/CN102655868A/zh active Pending
- 2010-12-10 PL PL10800713T patent/PL2437747T3/pl unknown
- 2010-12-10 LT LTEP10800713.9T patent/LT2437747T/lt unknown
- 2010-12-10 JP JP2012542570A patent/JP5907886B2/ja active Active
- 2010-12-10 BR BR112012014066A patent/BR112012014066A2/pt not_active Application Discontinuation
- 2010-12-10 RU RU2012128776/15A patent/RU2526161C2/ru active
- 2010-12-10 MX MX2012006206A patent/MX2012006206A/es active IP Right Grant
- 2010-12-10 PT PT108007139T patent/PT2437747T/pt unknown
- 2010-12-10 SI SI201031287A patent/SI2437748T1/sl unknown
- 2010-12-10 JP JP2012542571A patent/JP5984674B2/ja active Active
- 2010-12-10 DK DK10800713.9T patent/DK2437747T3/en active
- 2010-12-10 LT LTEP10800714.7T patent/LT2437748T/lt unknown
- 2010-12-10 CA CA2781576A patent/CA2781576C/en active Active
- 2010-12-10 US US13/142,577 patent/US8828946B2/en active Active
- 2010-12-10 PT PT108007147T patent/PT2437748T/pt unknown
- 2010-12-10 CA CA2781223A patent/CA2781223C/en active Active
- 2010-12-10 KR KR1020127017521A patent/KR101786444B1/ko active IP Right Grant
- 2010-12-10 SI SI201031285A patent/SI2437747T1/sl unknown
- 2010-12-10 WO PCT/EP2010/069427 patent/WO2011082951A1/de active Application Filing
- 2010-12-10 ES ES10800713.9T patent/ES2594766T3/es active Active
- 2010-12-10 KR KR1020127017525A patent/KR20120109542A/ko not_active Application Discontinuation
- 2010-12-10 BR BR112012013888A patent/BR112012013888A2/pt not_active Application Discontinuation
- 2010-12-10 RS RS20160830A patent/RS55251B1/sr unknown
-
2016
- 2016-09-29 CY CY20161100969T patent/CY1118081T1/el unknown
- 2016-10-04 CY CY20161100983T patent/CY1118044T1/el unknown
- 2016-10-04 HR HRP20161268TT patent/HRP20161268T1/hr unknown
- 2016-10-05 HR HRP20161279TT patent/HRP20161279T1/hr unknown
-
2017
- 2017-06-12 US US15/620,352 patent/US10537614B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161279T1 (hr) | Kombinirani preparati s antagonistom citokina i ortikosteroidom | |
CA2661422C (en) | Methods and compositions for treating cancer | |
AU774600B2 (en) | Pharmaceutical composition | |
US20220133749A1 (en) | Methods and compositions for treating cancer | |
RS53329B (en) | PROCEDURE AND MIXTURE FOR TREATMENT OF INFLAMMATORY DISORDERS | |
EP2214643B1 (en) | Transdermal delivery system for hormones and steroids | |
JP2018197259A5 (hr) | ||
JP2011502172A5 (hr) | ||
CO4960649A1 (es) | Esmalte para unas que contiene al menos un glucocorticoide y procedimiento de fabricacion | |
RU2017129432A (ru) | Лекарственные препараты для жирового тела сустава и способы их применения | |
JP2016515587A5 (hr) | ||
JP2005508983A5 (hr) | ||
US20190358344A1 (en) | Mineral coated microparticles for sustained delivery of steroids | |
AU2005263551B2 (en) | Use of a steroid for enhancement of skin permeability | |
AR089839A1 (es) | Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular | |
RU2007124549A (ru) | Средство, усиливающее действие адренокортикоидов, содержащее аравийскую камедь | |
JP2011503109A5 (hr) | ||
JP2008534566A5 (hr) | ||
Shahinfar et al. | Enigma of Intramuscular Triamcinolone Acetonide (Kenalog®) Efficacy | |
HRP20200460T1 (hr) | Postupci za liječenje dlbcl | |
JPWO2021072063A5 (hr) |